Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
A phase 1/2 trial of NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers. in uveal melanoma, run by Novelwise Pharmaceutical Corporation, now recruiting.
Overview
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma is a phase 1/2 interventional study registered as NCT07136181 by Novelwise Pharmaceutical Corporation, with 36 participants planned, started 2025-11-20 and due to reach its primary completion in 2028-03-28. Interventions recorded: NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers..
Similar pages
not linked directly; found by shared links- TrialA Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
Shares Uveal melanoma and the tag pipeline.
- TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Shares Uveal melanoma and the tag pipeline.
- TrialA Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Shares Uveal melanoma and the tag pipeline.
- TrialA Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Shares Uveal melanoma and the tag pipeline.
- TrialA Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
Shares Uveal melanoma and the tag pipeline.
- TreatmentDarovasertib
Shares Uveal melanoma and the tag pipeline.